Can-Fite BioPharma Ltd. announced new pre-clinical findings demonstrating that Namodenoson, inhibits lipid production and fat accumulation in adipocytes (lipid producing cells). These findings together with the excellent safety profile of Namodenoson support its potential utilization as an anti-obesity drug. New pre-clinical studies of Namodenoson showed a significant decrease in lipid production and fat accumulation utilizing 3T3-L1 adipocytes, functioning as lipid producing cells and are also responsible for fat storage. Namodenoson was also shown to inhibit the proliferation of adipocytes, further hampering the expansion of fat producing cells. A patent application for the utilization of Namodenoson as an anti-obesity drug has been filed. Can Fite is currently enrolling patients for a Phase II study of Namodenoson in NAFLD/NASH patients with evidence of active inflammation. The primary study end point is serum ALT levels, and secondary end point is percentage of liver fat, as measured by PDFF (proton density fat fraction). In addition, the Company expects to release data from its Phase II advanced liver cancer study of Namodenoson during first quarter 2019.